Stock analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get a rating) to show sales of $157.21 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made earnings estimates for Supernus Pharmaceuticals. The lowest sales estimate is $150.31 million and the highest is $164.10 million. Supernus Pharmaceuticals reported sales of $130.93 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.1%. The company is due to announce its next results on Monday, January 1.
On average, analysts expect Supernus Pharmaceuticals to record annual revenue of $680.14 million for the current fiscal year, with estimates ranging from $677.00 to $683.28 million. For the next fiscal year, analysts expect the company to record sales of $610.80 million, with estimates ranging from $600.12 million to $629.18 million. Zacks sales calculations are an average based on a survey of analysts who provide coverage for Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get a rating) last announced its quarterly results on Wednesday, April 13. The specialty pharmaceutical company reported earnings per share (EPS) of $0.04 for the quarter, missing Thomson Reuters consensus estimate of $0.29 per ($0.25). Supernus Pharmaceuticals had a net margin of 14.49% and a return on equity of 10.56%.
Several equity research analysts have recently released SUPN stock reports. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a Friday, March 4 report. StockNews.com began covering Supernus Pharmaceuticals in a report on Thursday, March 31. They set a “holding” rating for the company.
Shares of Supernus Pharmaceuticals Shares opened at $31.10 on Friday. The company has a market capitalization of $1.66 billion, a price-earnings ratio of 31.73 and a beta of 1.10. The company has a debt ratio of 0.46, a current ratio of 2.85 and a quick ratio of 2.59. Supernus Pharmaceuticals has a 52 week low of $23.15 and a 52 week high of $34.50. The stock has a 50-day simple moving average of $31.48 and a 200-day simple moving average of $30.65.
Several hedge funds have recently changed their stock holdings. Frontier Capital Management Co. LLC increased its stake in shares of Supernus Pharmaceuticals by 5.4% in Q1. Frontier Capital Management Co. LLC now owns 651,355 shares of the specialty pharmaceutical company valued at $21,052,000 after acquiring 33,654 additional shares last quarter. Veriti Management LLC increased its stake in shares of Supernus Pharmaceuticals by 8.8% in Q1. Veriti Management LLC now owns 8,903 shares of the specialty pharmaceutical company valued at $288,000 after acquiring 720 additional shares last quarter. Maryland State Retirement & Pension System increased its stake in Supernus Pharmaceuticals shares by 2.2% in Q1. Maryland State Retirement & Pension System now owns 21,511 shares of the specialty pharmaceutical company valued at $695,000 after acquiring 460 additional shares last quarter. Everence Capital Management Inc. bought a new position in Supernus Pharmaceuticals stock in Q1 worth approximately $272,000. Finally, Norges Bank bought a new position in shares of Supernus Pharmaceuticals in Q4 valued at around $14,443,000.
Supernus Pharmaceuticals Company Profile (Get a rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Supernus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.